# Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD

Study · id `cardio:ct-nct06820567` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06820567](<https://clinicaltrials.gov/study/NCT06820567>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06820567

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 210 participants.

## Technical summary

Registry record NCT06820567. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-01 (anticipated); primary completion 2026-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 210 participants (planned count; ClinicalTrials.gov record NCT06820567, source copy `cardio:ctgov-nct06820567-2025-02-11`, retrieved 2026-10-26)
- Planned start: 2025-03-01 (anticipated) (ClinicalTrials.gov record NCT06820567, source copy `cardio:ctgov-nct06820567-2025-02-11`, retrieved 2026-10-26)
- Primary completion: 2026-03-01 (anticipated) (ClinicalTrials.gov record NCT06820567, source copy `cardio:ctgov-nct06820567-2025-02-11`, retrieved 2026-10-26)
- Completion: 2027-05-01 (anticipated) (ClinicalTrials.gov record NCT06820567, source copy `cardio:ctgov-nct06820567-2025-02-11`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06820567-2025-02-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients With Type 2 Diabetes and CKD
- Condition: Chronic Kidney Diseases
- Condition: Diabetes Type 2
- Intervention (Drug): Dapagliflozin (DAPA)
- Intervention (Drug): Placebo
- Lead sponsor: Assiut University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Assiut University (`cardio:org-assiut-university`)

## Provenance

Content hash: 455bfee524015d0b00dbeb32285823dc926836a61189b3dae506312c81f5fda3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
